Skip to main content
OpenTrials

Clinical trial condition

Adenocarcinoma

Explore clinical trials studying Adenocarcinoma. Study availability and eligibility vary by location and protocol.

5,027 public trials 1,169 recruiting studies
Refine in advanced search Browse all conditions

Adenocarcinoma trial results

Recruiting

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +16 more
Locations
  • University of California San Diego La Jolla, California, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Columbia University Irving Medical Center New York, United States
View Trial Details
Recruiting

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +32 more
Locations
  • Oncology Physicians Network (OPN) - Glendale Glendale, California, United States
  • Oncology Physicians Network (OPN)- Los Alamitos Los Alamitos, California, United States
  • HCA Los Angeles, California, United States
  • Los Angeles Cancer Network Los Angeles, California, United States
View all 69 locations
View Trial Details
Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985

Conditions
Adenocarcinoma, Advanced Solid Tumors, Bronchial Neoplasms, +45 more
Locations
  • UC Irvine/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCLA Santa Monica, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Piedmont Healthcare Atlanta, Georgia, United States
View all 21 locations
View Trial Details
Recruiting

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

NCT06708949

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Duke University Medical Center Durham, North Carolina, United States
  • Penn Medicine Abramson Cancer Center Philadelphia, Pennsylvania, United States
  • Vanderbilt University Medical Center Nashville, Tennessee, United States
View Trial Details

Related conditions